UK markets close in 4 hours 35 minutes
  • FTSE 100

    7,463.12
    -91.19 (-1.21%)
     
  • FTSE 250

    21,676.44
    -178.13 (-0.82%)
     
  • AIM

    1,079.30
    -7.34 (-0.68%)
     
  • GBP/EUR

    1.2028
    +0.0026 (+0.21%)
     
  • GBP/USD

    1.3392
    +0.0011 (+0.08%)
     
  • BTC-GBP

    27,230.33
    -273.09 (-0.99%)
     
  • CMC Crypto 200

    827.16
    +7.65 (+0.93%)
     
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • CRUDE OIL

    87.12
    +0.51 (+0.59%)
     
  • GOLD FUTURES

    1,784.90
    -10.10 (-0.56%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • HANG SENG

    23,550.08
    -256.92 (-1.08%)
     
  • DAX

    15,219.56
    -304.71 (-1.96%)
     
  • CAC 40

    6,908.98
    -114.82 (-1.63%)
     

Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb

·3-min read
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • GSK
  • BMY

In particular, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY) are two of the world's most preeminent pharmaceutical companies, but neither has consistently outperformed the market over the past five years. Right now, Bristol-Myers is in the doldrums. Over the past three years, its quarterly revenue has jumped 94.6% and quarterly net income has risen 33.3%.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting